FDA Warning Letter Issued to BMC Medical Over Unapproved CPAP Modifications and Failure to Report Firmware Safety Corrections

The United States Food and Drug Administration (FDA) has issued a formal warning letter to Beijing-based BMC Medical Co Ltd, a prominent manufacturer of sleep therapy equipment, following a series of regulatory violations involving the unauthorized modification of its positive airway pressure devices and a failure to report critical firmware corrections aimed at preventing unexpected system shutdowns. The regulatory action, which stems from an inspection of the company’s U.S. distribution partner, React Health Inc (formerly known as 3B Medical Inc), underscores the agency’s tightening grip on the sleep apnea device market following years of high-profile safety concerns across the industry.

The warning letter, dated May 20, 2026, highlights significant deviations from the Federal Food, Drug, and Cosmetic Act, specifically regarding the introduction of "adulterated and misbranded" medical devices into interstate commerce. According to the FDA, BMC Medical implemented substantial design and material changes to its Luna CPAP and Auto CPAP systems without obtaining the necessary premarket notification—commonly known as a 510(k) clearance—which is required to ensure that such modifications do not compromise patient safety or device efficacy.

Regulatory Oversight and the Inspection of React Health

The path to the warning letter began in December 2025, when FDA investigators conducted an onsite inspection of React Health’s facility in Dublin, Ohio. React Health serves as the primary importer and distributor for BMC Medical products in the United States. During the inspection, the FDA determined that BMC Medical, while headquartered in Beijing, remains the legal specification developer and the owner of the 510(k) clearances for the devices in question.

The inspection revealed that BMC Medical had been marketing and distributing a new model, the G3X APAP, which the FDA contends is a significant departure from the Luna CPAP and Auto CPAP System originally cleared by the agency in 2016. Under federal law, if a manufacturer makes a change to a cleared device that could significantly affect its safety or effectiveness, or if there is a major change in its intended use, a new 510(k) submission is mandatory. The FDA’s findings suggest that BMC Medical bypassed this critical step, effectively placing unvetted technology into the hands of American consumers and healthcare providers.

Technical Deviations: Algorithms, Hardware, and Biocompatibility

The FDA’s concerns are rooted in several layers of technical modifications that BMC Medical applied to the G3X APAP. Central to the agency’s complaint are updates to the device’s firmware and software. The G3X model introduced new recognition features designed to identify flow limitation, respiratory effort-related arousals (RERAs), and periodic breathing. These features were intended to help the device distinguish between central and obstructive hypopnea events—a critical distinction in sleep medicine, as the treatments for neurological (central) and physical (obstructive) sleep apnea differ significantly.

The FDA noted that these algorithm changes are not merely incremental; they fundamentally alter the accuracy of event classification. For clinicians relying on the data generated by these devices to manage patient care, inaccurate classification can lead to suboptimal therapy settings, potentially leaving a patient’s sleep apnea undertreated.

Beyond software, the FDA detailed physical hardware changes that raise further safety questions. The agency discovered that the sound abatement system of the previously cleared Luna APAP had been modified. In the context of CPAP devices, the sound abatement system is part of the "gas pathway"—the route through which air travels from the machine to the patient’s lungs. Any change to the materials in the gas pathway necessitates rigorous biocompatibility testing to ensure that the materials do not off-gas harmful chemicals or shed particulates that a patient could inhale. The FDA stated that BMC Medical failed to provide the necessary evidence that these material changes were safe.

Furthermore, the printed circuit board assembly (PCBA) was updated with a new chip to handle the more complex algorithms of the G3X model. The FDA maintains that the combination of new hardware, modified materials, and unvetted software constitutes a "new" device that required independent regulatory review before it could be legally sold.

Failure to Report Life-Safety Firmware Corrections

Perhaps the most pressing safety concern cited in the warning letter involves the Luna G3 APAP devices and their propensity for unexpected shutdowns. The FDA’s investigation revealed that devices running firmware version G3-2.00.76 were susceptible to shutting down during use without warning. For a patient suffering from obstructive sleep apnea (OSA), an unexpected loss of therapy during the night can result in immediate hypoxia (low blood oxygen), fragmented sleep, and increased cardiovascular strain.

To address this defect, BMC Medical developed and initiated a firmware update (version G3-2.00.77). However, the FDA classified this update as a "medical device correction" intended to reduce a risk to health. Under 21 CFR Part 7, manufacturers are required to report such corrections or removals to the FDA within 10 working days of initiation. As of mid-May 2026, the FDA stated it had received no such report from BMC Medical, representing a significant lapse in the company’s post-market surveillance and reporting obligations.

The Broader Context: A Scrutinized Sleep Therapy Market

The enforcement action against BMC Medical arrives at a time when the sleep apnea device market is under unprecedented scrutiny. The industry is still reeling from the massive 2021 recall of millions of Philips Respironics CPAP and BiPAP machines, which were found to contain sound-abatement foam that could degrade and become toxic. That crisis led to a global shortage of devices and a heightened awareness among regulators regarding the materials used in the gas pathways of respiratory equipment.

In the wake of the Philips recall, companies like BMC Medical and React Health saw an opportunity to capture market share. However, the FDA’s recent warning letter serves as a reminder that rapid expansion cannot come at the expense of regulatory compliance. The agency has signaled that it will no longer tolerate "silent" updates or modifications that bypass the 510(k) process, especially when those changes involve the very components—software algorithms and sound-abatement materials—that are critical to patient safety.

Chronology of Regulatory Friction

The timeline of the FDA’s interaction with BMC Medical and React Health highlights a period of increasing tension:

• 2016: BMC Medical receives 510(k) clearance for the original Luna CPAP and Auto CPAP System.
• 2021–2024: Following the Philips recall, BMC Medical expands its footprint in the U.S. market, introducing newer iterations of the Luna line.
• December 2025: The FDA conducts a multi-day inspection of React Health’s Dublin, Ohio facility, uncovering discrepancies between cleared device specifications and the products being sold.
• Early 2026: BMC Medical identifies a shutdown bug in firmware version G3-2.00.76 and begins rolling out version G3-2.00.77 as a fix but fails to notify the FDA of this corrective action.
• May 20, 2026: The FDA officially issues the warning letter, categorizing the G3X APAP as adulterated and misbranded.

Potential Implications for Clinicians and Patients

The FDA’s warning has immediate implications for the thousands of patients currently using BMC-manufactured devices distributed by React Health. While the FDA has not yet issued a formal mandatory recall of all G3X units, the "adulterated and misbranded" designation often serves as a precursor to such actions if the manufacturer fails to rectify the issues.

For clinicians, the primary concern lies in the reliability of the diagnostic data. If the unapproved algorithms are inaccurately reporting RERAs or distinguishing poorly between central and obstructive events, the clinical management of the patient could be flawed. Sleep specialists may need to review the data from patients using these specific models to ensure that the therapy remains effective.

Furthermore, the issue of unexpected shutdowns poses a direct physical risk. Patients are advised to check their device’s firmware version. If a device is running the G3-2.00.76 version, it is at risk of failure, and while the G3-2.00.77 update exists, the FDA’s lack of oversight on this correction means the agency has not yet verified that the fix is fully effective or that the rollout has reached all affected users.

Official Responses and Next Steps

As of the date of the warning letter’s publication, neither BMC Medical nor React Health has provided a public comment regarding the FDA’s allegations. The FDA has given BMC Medical 15 business days to respond in writing, detailing the specific steps the company has taken to correct the violations and prevent their recurrence.

Failure to address the concerns listed in the warning letter could result in more severe consequences, including:

1. Seizure of Products: Federal marshals could be authorized to seize existing inventory of the G3X and related devices.
2. Injunctions: The FDA could seek a court order to prevent BMC Medical and React Health from distributing any further devices in the U.S. until compliance is met.
3. Civil Money Penalties: Substantial fines could be levied against the companies for failing to report the firmware correction and for marketing unapproved devices.
4. Import Bans: The FDA could place BMC Medical on an import alert list, effectively blocking their products at the border.

Industry Analysis: The High Cost of Non-Compliance

Industry analysts suggest that the FDA’s move against BMC Medical is a "shot across the bow" for the entire medical device sector. In an era where software-as-a-medical-device (SaMD) and firmware-driven hardware are becoming the norm, manufacturers often feel pressured to iterate quickly to stay competitive. However, the FDA’s stance is clear: any modification that touches the "core" of the device’s performance—its algorithms or its physical air path—must be transparently reviewed.

"The sleep therapy market is in a fragile state," says one industry consultant. "Trust is the most valuable currency right now. When a manufacturer fails to report a safety correction for something as serious as a device shutting down mid-therapy, it erodes the trust of the FDA, the physicians, and most importantly, the patients."

The situation also places React Health in a difficult position. As the "face" of the product in the United States, React Health must navigate the fallout of its partner’s regulatory failures. The company may face significant logistical challenges if it is required to facilitate a massive recall or hardware replacement program for the sound-abatement system.

Conclusion

The FDA’s warning letter to BMC Medical Co Ltd serves as a critical juncture for the company and its U.S. partner, React Health. As the agency demands transparency and adherence to the 510(k) clearance process, the focus remains on ensuring that sleep apnea patients receive therapy that is not only effective but consistently safe. The coming weeks will be decisive as BMC Medical prepares its response, and the sleep medicine community waits to see if this regulatory friction will lead to a broader market disruption or a swift path to compliance. For now, the G3X APAP remains under a cloud of regulatory uncertainty, a reminder of the rigorous standards required to maintain a presence in the American medical device market.